Every aesthetic practitioner obtains informed consent. Few consider that the act of obtaining it may itself be causing harm. The nocebo effect, the induction of adverse symptoms through negative expectation, is one of the most robustly evidenced and most consistently ignored phenomena in clinical medicine.

Decades of research across pain medicine, surgery, and clinical pharmacology have established that explicitly communicating expected symptoms to a patient reliably increases the incidence and severity of those symptoms, independent of any treatment effect. The mechanisms are not psychological in the dismissive sense of that word. They are neurobiological: cholecystokinin release driving anxiety mediated pain sensitisation, hypothalamic-pituitary-adrenal axis activation elevating inflammatory tone and altered anterior cingulate and insular cortex activity reshaping the patient’s interoceptive experience before a needle has even been placed.

Standard aesthetic consent language enumerates bruising, swelling, pain, tenderness and prolonged recovery as expected outcomes, framed in the imperative register of clinical disclosure. This language is legally defensible. It is also, by the established criteria of the nocebo literature, a priming protocol for the symptoms it describes. This keynote examines the evidence base for nocebo mechanisms in clinical settings, maps that evidence onto the structure of routine aesthetic consultations and challenges the assumption that how we communicate risk is clinically neutral. It does not argue against full disclosure. It argues that communication design, encompassing language framing, sequencing, and expectation calibration, is a clinical skill with measurable patient outcome consequences that aesthetic medicine has not yet recognised as such. The question this talk asks is not whether we should inform our patients. It is whether we have examined what we are doing to them when we do.